Browsing Tag
Omvoh
5 posts
Can Eli Lilly and Company’s Omvoh reset expectations for long-term Crohn’s disease control?
Three-year Omvoh data shows durable steroid-free remission in Crohn’s disease. Read how this reshapes Eli Lilly and Company’s long-term strategy.
Lilly’s Omvoh sets a new benchmark in ulcerative colitis with four-year steroid-free remission data
Eli Lilly’s Omvoh (mirikizumab-mrkz) delivers four years of steroid-free remission in ulcerative colitis patients according to LUCENT-3 data. Discover how this sets a new benchmark for IBD therapy.
Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion,…
Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal,…
FDA approves Lilly’s Omvoh: A breakthrough for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has sanctioned Eli Lilly and Company’s Omvoh (mirikizumab-mrkz) infusion (300 mg/15…